Search Result

Results for "

PD-1/PD-L1 interaction

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (82) Akt (1) Apoptosis (6) AUTACs (1) Autophagy (1) Drug-Linker Conjugates for ADC (1) HBV (1) HDAC (2) Histone Demethylase (1) IFNAR (1) Interleukin Related (2) LAG-3 (1) Ligands for Target Protein for PROTAC (1) NAMPT (1) PARP (2) PI3K (1) PROTACs (1) Target Protein Ligand-Linker Conjugates (2) TNF Receptor (1) Toll-like Receptor (TLR) (1) VISTA (1)
By Research Areas:	Cancer (77) Infection (5) Inflammation/Immunology (27) Metabolic Disease (1)
Click Chemistry:	DBCO (1) Azide (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Click Chemistry

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116274

BMS-8	PD-1/PD-L1	Cancer
BMS-8 inhibits the *PD-1/PD-L1* interaction with IC₅₀ of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1 .

HY-132192

PD-1/PD-L1-IN-9 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-132192A

PD-1/PD-L1-IN-9 hydrochloride 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 .

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein inhibitor with a K_d** value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to *PD-L1. Garivulimab selectively blocks the interaction* of PD-L1 and PD-1. Garivulimab has antitumor activity .

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 .

HY-158052

PD-1/PD-L1 antagonist 1	PD-1/PD-L1	Cancer
PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC₅₀ of 23.78 nM .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-P99641

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1. Gilvetmab can be used in malignant melanoma research .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with *PD-L1* and *PD-L2* (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

HY-P9972

Spartalizumab PDR001	PD-1/PD-L1	Cancer
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds *PD-1* with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) .

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a *humanized anti-PD-L1* antibody** (IgG1κ type). Tagitanlimab selectively blocks the interaction of *PD-L1* and *PD-1*. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .

HY-102011

BMS-1166 3 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 is a potent *PD-1/PD-L1* immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-102011A

BMS-1166 hydrochloride 3 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 hydrochloride is a potent *PD-1/PD-L1* immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with *PD-L1* and *PD-L2*. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- *PD-L1* antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .

HY-155959

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity .

HY-163534

PD-1/PD-L1-IN-43	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the *PD-1/PD-L1* interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between *PD-1* and *PD-L1. PD-1/PD-L1*-IN-43 can be used in anti-tumor studies .

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .

HY-168081

PD-1/PD-L1-IN-52	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active *PD-1/PD-L1* inhibitor that blocks the interaction between **PD-1 and PD-L1, with an IC₅₀** of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99048A

Sintilimab (Anti-PD-1) IBI308 (Anti-PD-1)	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-159892

PD-1/PD-L1-IN-54	PD-1/PD-L1 IFNAR Interleukin Related PI3K Akt	Cancer
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic *PD-1/PD-L1* inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8 ⁺ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1 .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor *PD-1* antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-P10424

OPBP-1	PD-1/PD-L1	Cancer
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind *PD-L1* protein, significantly block the interaction between *PD-1* and *PD-L1*, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research .

HY-152240

PD-1/PD-L1-IN-29	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity .

HY-144258

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 .

HY-P99052

Tislelizumab 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

HY-120402

BMS-200	PD-1/PD-L1	Inflammation/Immunology
BMS-200 is a potent **PD-1/PD-L1 interaction inhibitor with an IC₅₀** of 80 nM. BMS-200 can induce dimerization of PD-L1 .

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
PL120131 is a *PD-1/PD-L1* inhibitory peptide that can interfere with the interaction of *PD-1/PD-L1* by binding to *PD-1. PL120131 is capable of inhibiting the PD-1*-mediated apoptotic signaling pathway, protecting Jurkat cells and primary lymphocytes from apoptosis. PL120131 aids in the antitumor activity of cytotoxic T lymphocytes (CTLs) .

HY-163958

PD-L1-IN-7	PD-1/PD-L1	Cancer
PD-L1-IN-7 (compound CB31) is an inhibitor of *PD-L1, which can induce PD-L1* internalization and PD-L1 retention in cells. PD-L1-IN-7 can inhibit the interaction of PD-1/PD-L1 (IC₅₀: 0.2 nM), change the glycosylation pattern, and promote PD-L1 degradation. PD-L1-IN-7 can also enhance T cell infiltration, amplify T cell function and the ability to kill tumor cells .

HY-128605

PD-1-IN-22	PD-1/PD-L1	Cancer
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC₅₀ of 92.3 nM .

HY-19745B

BMS-202 hydrochloride	PD-1/PD-L1 Apoptosis	Cancer
BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC₅₀ of 18 nM and a K_D of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity .

HY-19745

BMS-202 15+ Cited Publications	PD-1/PD-L1 Apoptosis	Cancer
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC₅₀ of 18 nM and a K_D of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity .

HY-120646

BMS-242	PD-1/PD-L1	Others
BMS-242 is a small molecule PD-1/PD-L1 inhibitor with the activity of inhibiting the PD-1/PD-L1 interaction. BMS-242 can bind to the hydrophobic channel pocket between PD-L1 molecules, inhibit the PD-1/PD-L1 immune checkpoint pathway, and provide a new way for cancer inhibition.

HY-162356

PD-L1-IN-4	PD-1/PD-L1	Cancer
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific *PD-1/LAG-3* dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-168080

PD-1/PD-L1-IN-51	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-51 (Compound III-4) is a *PD-1/PD-L1* inhibitor (IC₅₀: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity .

HY-154869

PD-1/PD-L1-IN-34	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits *PD-1/PD-L1* interaction (IC₅₀=0.029 μM), with a selected binding affinity with PD-L1 (K_D=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment .

HY-169363

PDL1 degrader-2	PD-1/PD-L1 Autophagy AUTACs	Cancer
PD-L1 degrader-2 (Compound B3) is an orally active AUTAC degrader, that degrades *PD-L1* through autophagy-lysosome pathway with a DC₅₀ of 0.5 μM. PD-L1 degrader-2 exhibits inhibitory activity against PD-1/PD-L1 interaction with an IC₅₀ of 22.8 nM. PD-L1 degrader-2 upregulates the expressions of Atg9b, Lamp1 and Mitf, and activates the autophagy lysosome system. PD-L1 degrader- exhibits antitumor efficacy in CT26 mouse model . (Pink: autophagy-lysosome activator (HY-159894); Black: linker (HY-W015088); Blue: PD-L1 ligand (HY-169365))

HY-169392

D5B	PD-1/PD-L1	Cancer
D5B is a potent and selective *PD-L1* inhibitor. D5B has been modified by DBCO. The EC₅₀ of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity .

HY-131183

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a *PD-1/PD-L1* PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .

HY-172167

PD-L1/HDAC-IN-1	PD-1/PD-L1 HDAC	Inflammation/Immunology Cancer
PD-L1/HDAC-IN-1 (Compound 14) is the inhibitor for *PD-L1* and HDAC that inhibits *PD-1/PD-L1* interaction, HDAC2 and HDAC3 with IC₅₀ of 88.10, 27.98 and 14.47 nM, respectively. PD-L1/HDAC-IN-1 exhibits slight cytotoxicity in MCF-7 (IC₅₀=19.34 μM). PD-L1/HDAC-IN-1 upregulates the expression of PD-L1 and CXCL10, promoting anti-tumour immune response by recruiting T-cell infiltration into TME .

HY-170793

PD-L1/VISTA-IN-1	PD-1/PD-L1 VISTA	Cancer
PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual-target inhibitor of *PD-L1* and VISTA. PD-L1/VISTA-IN-1 can block the *PD-1/PD-L1* interaction (IC₅₀: 0.1492 μM) and the VISTA pathway (K_D: 0.2723 μM), thereby reactivating T cells. PD-L1/VISTA-IN-1 has anti-tumor activity .

Cat. No.	Product Name

HY-L109

Protein-protein Interaction Inhibitor Library

656 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 656 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area